Safety and efficacy of first-line nivolumab plus chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: real-world data analysis

Background: This study aimed to evaluate the safety and efficacy of first-line nivolumab plus chemotherapy for real-world patients with human epidermal growth factor receptor 2 (HER2)-negative advanced gastric cancer (AGC). Materials and methods: This single-institutional retrospective study enrolle...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	K. Shimozaki, K. Fukuda, A. Ooki, I. Nakayama, K. Yoshino, M. Tamba, S. Udagawa, S. Fukuoka, H. Osumi, T. Wakatsuki, D. Takahari, E. Shinozaki, M. Ogura, K. Chin, K. Yamaguchi
Format:	Artigo
Sprog:	Inglês
Udgivet:	Elsevier 2024-09-01
Serier:	ESMO Gastrointestinal Oncology
Fag:	gastric or gastroesophageal junction cancer nivolumab PD-L1 early tumor shrinkage depth of response
Online adgang:	http://www.sciencedirect.com/science/article/pii/S2949819824000335
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!